@article {Boone2021.05.07.21256326, author = {Megann A. Boone and Cenny Taslim and Jesse C. Crow and Julia Selich-Anderson and Mike Watson and Peter Heppner and James Hamill and Andrew C. Wood and Stephen L. Lessnick and Mark Winstanley}, title = {Identification of a novel FUS/ETV4 fusion and comparative analysis with other Ewing sarcoma fusion proteins}, elocation-id = {2021.05.07.21256326}, year = {2021}, doi = {10.1101/2021.05.07.21256326}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Ewing sarcoma is an aggressive pediatric bone cancer defined by a chromosomal translocation fusing one of the FET family members to a member of the ETS transcription factor family. To date, there have been seven reported translocations, with the most recent translocation reported over a decade ago. We now report the first identification of a novel translocation occurring between the FUS gene and ETS family member ETV4 detected in a neonatal patient with Ewing sarcoma. Given its apparent rarity, we conducted an initial characterization of FUS/ETV4 function by performing genomic localization and transcriptional regulatory studies. We knocked down endogenous EWS/FLI in the A673 cell line, and expressed FUS/ETV4 in its stead, and performed CUT\&Tag and RNA-sequencing analyses. We compared these data to similar {\textquotedblleft}knock-down/rescue{\textquotedblright} analyses of other rare (non-EWS/FLI) Ewing sarcoma-associated translocation products. Through this comparative analysis in the same genetic background, we demonstrate significant similarities across these fusions, and in doing so, validate this novel FUS/ETV4 translocation as a bona fide Ewing sarcoma translocation. This study presents the first genomic comparisons of the rare Ewing sarcoma-associated translocation products, and reveals that the FET/ETS fusions share highly similar, but not identical, genomic localization and transcriptional regulation patterns. These data provide insights into the roles of both the FET and ETS sides of these fusions, and provide a generic strategy to provide further strength to the notion that FET/ETS fusions are key drivers of, and thus pathognomonic for, Ewing sarcoma.Significance Identification and initial characterization of the novel Ewing sarcoma fusion, FUS/ETV4, expands the family of Ewing-fusions and extends the diagnostic possibilities for this aggressive tumor of adolescents and young adults.Competing Interest StatementResearch reported in this publication was supported by the National Institutes of Health award U54 CA231641 to SLL. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SLL declares a competing interest as a member of the advisory board for Salarius Pharmaceuticals. SLL is also a listed investor on United States Patent No. US 7,939,253 B2, Methods and compositions for the diagnosis and treatment of Ewings sarcoma, and United States Patent No. US 8,557,532, Diagnosis and treatment of drug-resistant Ewings sarcoma.Funding StatementResearch reported in this publication was supported by the National Institutes of Health award U54 CA231641 to SLL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nationwide Children{\textquoteright}s Hospital Institutional Review Board determined that this project was not classified as human subjects research and was therefore exempt from review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequencing datasets generated and analyzed during the current study are available in the Gene Expression Omnibus and accessible at GSE173185. All other data generated or analyzed during this study are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/05/09/2021.05.07.21256326}, eprint = {https://www.medrxiv.org/content/early/2021/05/09/2021.05.07.21256326.full.pdf}, journal = {medRxiv} }